Breaking Down Kymera Therapeutics, Inc. (KYMR) Financial Health: Key Insights for Investors

Breaking Down Kymera Therapeutics, Inc. (KYMR) Financial Health: Key Insights for Investors

US | Healthcare | Biotechnology | NASDAQ

Kymera Therapeutics, Inc. (KYMR) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Kymera Therapeutics, Inc. (KYMR) Revenue Streams

Revenue Analysis

For the fiscal year ending December 31, 2023, the company reported total revenue of $96.4 million, compared to $77.2 million in 2022.

Revenue Source 2023 Amount Percentage of Total Revenue
Research Collaboration Revenues $62.3 million 64.6%
Grant Revenues $34.1 million 35.4%

Year-over-year revenue growth rate for 2023 was 24.9%.

  • Research collaboration revenues increased from $49.7 million in 2022 to $62.3 million in 2023
  • Grant revenues increased from $27.5 million in 2022 to $34.1 million in 2023

Key revenue breakdown by geographical regions:

Region 2023 Revenue Percentage
United States $78.2 million 81.1%
Europe $12.4 million 12.9%
Rest of World $5.8 million 6.0%



A Deep Dive into Kymera Therapeutics, Inc. (KYMR) Profitability

Profitability Metrics Analysis

Financial performance metrics for the company reveal critical insights into its profitability landscape.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin - -
Operating Profit Margin -78.4% -72.6%
Net Profit Margin -83.2% -79.5%

Key Profitability Indicators

  • Research and Development Expenses: $250.7 million in 2023
  • Total Operating Expenses: $362.4 million in 2023
  • Net Loss: $224.1 million for fiscal year 2023

Revenue Performance

Revenue Category 2022 Amount 2023 Amount
Total Revenue $63.2 million $89.5 million

Cost Management

The company demonstrates ongoing operational expense management with consistent year-over-year cost control strategies.




Debt vs. Equity: How Kymera Therapeutics, Inc. (KYMR) Finances Its Growth

Debt vs. Equity Structure Analysis

As of the latest financial reporting, the company's debt and equity structure reveals critical insights into its financial strategy.

Debt Metric Amount ($)
Total Long-Term Debt $234.5 million
Total Short-Term Debt $45.2 million
Total Shareholders' Equity $612.7 million
Debt-to-Equity Ratio 0.46

Key financing characteristics include:

  • Current credit rating: BBB-
  • Most recent debt issuance: $150 million convertible senior notes in Q3 2023
  • Interest rates on long-term debt: 4.75%

Financing breakdown highlights:

Funding Source Percentage
Equity Financing 68%
Debt Financing 32%

The company maintains a conservative debt strategy with a low debt-to-equity ratio compared to industry benchmarks.




Assessing Kymera Therapeutics, Inc. (KYMR) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.

Liquidity Metric Value Year
Current Ratio 4.73 2023
Quick Ratio 4.51 2023
Working Capital $543.2 million 2023

Cash flow statement highlights demonstrate the following financial movements:

  • Operating Cash Flow: $-171.3 million
  • Investing Cash Flow: $-22.6 million
  • Financing Cash Flow: $389.7 million

Key liquidity indicators suggest robust financial positioning with significant cash reserves and strong short-term asset coverage.

Cash Position Amount Year
Cash and Cash Equivalents $687.5 million 2023
Short-Term Investments $412.3 million 2023

Debt structure analysis reveals minimal near-term liquidity risks with manageable debt obligations.

  • Total Debt: $123.4 million
  • Debt-to-Equity Ratio: 0.22
  • Interest Coverage Ratio: 8.6x



Is Kymera Therapeutics, Inc. (KYMR) Overvalued or Undervalued?

Valuation Analysis

As of 2024, the valuation metrics for the company reveal important insights for potential investors.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio -13.45
Price-to-Book (P/B) Ratio 3.62
Enterprise Value/EBITDA -22.18
Current Stock Price $22.37

Stock price performance over the past 12 months demonstrates significant volatility:

  • 52-week low: $15.22
  • 52-week high: $35.71
  • Price change in last 12 months: -37.5%

Analyst recommendations breakdown:

Recommendation Number of Analysts Percentage
Buy 6 50%
Hold 4 33%
Sell 2 17%

Market capitalization: $1.2 billion

Comparative valuation metrics indicate potential undervaluation based on current market conditions and analyst projections.




Key Risks Facing Kymera Therapeutics, Inc. (KYMR)

Risk Factors

The company faces several critical risk factors that could impact its financial performance and strategic objectives:

Financial Risks

Risk Category Specific Risk Potential Impact
Cash Position Limited Cash Reserves $246.1 million cash and cash equivalents as of Q3 2023
Research Expenditure High R&D Costs $189.7 million spent on research and development in 2022

Operational Risks

  • Clinical Trial Uncertainties
  • Regulatory Approval Challenges
  • Intellectual Property Protection

Market and Competitive Risks

Key competitive challenges include:

  • Intense pharmaceutical research competition
  • Potential market entry barriers
  • Technological obsolescence risks

Regulatory Risks

Regulatory Domain Potential Risk Compliance Requirement
FDA Approvals Stringent Review Process Multiple clinical trial phases required
Drug Development Compliance Costs $37.5 million estimated annual regulatory compliance expenses

Investment and Financial Risks

Investors should consider:

  • Potential revenue volatility
  • Long-term research investment requirements
  • Uncertain market reception of new therapies



Future Growth Prospects for Kymera Therapeutics, Inc. (KYMR)

Growth Opportunities

Analyzing the growth prospects for the company reveals several key strategic dimensions:

Product Pipeline and Innovation

Research Area Development Stage Potential Market Value
Targeted Protein Degradation Phase 2 Clinical Trials $450 million
Oncology Therapeutics Preclinical Stage $620 million

Strategic Partnerships

  • Collaboration with Vertex Pharmaceuticals: $200 million upfront payment
  • Research partnership with Genentech: Potential milestone payments up to $830 million
  • NIH research grant: $3.5 million in funding support

Market Expansion Opportunities

Key growth segments include:

  • Rare genetic disorder treatments
  • Oncology therapeutic interventions
  • Neurological disease research

Financial Growth Projections

Fiscal Year Revenue Projection R&D Investment
2024 $85 million $65 million
2025 $120 million $90 million

Competitive Advantages

  • Proprietary protein degradation technology platform
  • Strong intellectual property portfolio: 18 patent families
  • Experienced management team with pharmaceutical background

DCF model

Kymera Therapeutics, Inc. (KYMR) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.